藥明合聯(02268.HK)升6%破頂 藥明生物(02269.HK)藥明康德(02359.HK)各創52周高 花旗料領先CDMO公司中績勝預期
花旗稱,料領先內地醫藥股/生物製藥股今年上半年業績有望勝預期,受惠對外授權交易及強勁創新藥銷售增長。領先合同研發生產組織(CDMO) .公司上半年業績有望勝預期,受強勁積壓訂單支撐。
藥明系主要企業今早(24日)全線造好。藥明合聯(02268.HK)今早(24日)高開2.1%,早段升幅擴大,高見57.7元創歷史高。現報56.85元,升5.96%,成交571.91萬股,涉資3.2億元。
藥明生物(02269.HK)今早高見30.15元,突破52周高位,兼創近一年半高。現報29.85元,升3.83%,成交4,027.7萬股,涉資11.81億元。
藥明康德(02359.HK)今日平開,最高見96元,突破52周高位,兼創2023年11月以來逾一年半高。現報95.45元,升2.47%,成交403.43萬股,涉資3.83億元。
花旗予藥明生物(02269.HK)「買入」評級,目標價35元。花旗予藥明合聯(02268.HK)「買入」評級,目標價46元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.